Search
Now showing items 1-9 of 9
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial
(2018)
Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing ...
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy
(2020)
Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of undetermined ...
Implantação da Estratégia e-SUS Atenção Básica: uma análise fundamentada em dados oficiaisImplementation of the e-SUS primary care strategy: an analysis based on official data
(Universidade de São Paulo. Faculdade de Saúde Pública, 2023)
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial
(2020-10)
Importance: The reported associations of cerebral microbleeds with recurrent stroke and intracerebral hemorrhage have raised concerns regarding antithrombotic treatment in patients with a history of stroke and microbleeds ...
Processo de implantação do e-SUS Atenção Básica em Sobral – CE
(2018)
Criado pelo Ministério da Saúde (MS), o e-SUS AB vem com a finalidade de reorganizar os dados da atenção básica e reestruturar os sistemas de informação em saúde. O objetivo do estudo que fundamenta este artigo foi conhecer ...
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
(2018)
Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with ...
Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana Project
(Frontiers Research Foundation, 2023)